Publications by authors named "Adam Curnock"

Claim this Profile
C
Cell-targeted PD-1 agonists that mimic PD-L1 are potent T cell inhibitors.
Adam P Curnock, Giovanna Bossi, Jyothi Kumaran, Lindsay J Bawden, Rita Figueiredo

JCI Insight· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Selective, Orally Bioavailable Pyrazolopyridine Inhibitors of Protein Kinase Cθ (PKCθ) That Ameliorate Symptoms of Experimental Autoimmune Encephalomyelitis.
Philip N Collier, Heather C Twin, Ronald M A Knegtel, Dean Boyall, Guy Brenchley, Adam Curnock

ACS Med Chem Lett· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification and characterization of Nanobodies targeting the EphA4 receptor.
Lies Schoonaert, Laura Rué, Bart Roucourt, Mieke Timmers, Susan Little, Adam Curnock

J Biol Chem· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective protein kinase Cθ (PKCθ) inhibitors for the treatment of autoimmune diseases.
Adam Curnock, Clare Bolton, Peter Chiu, Elisabeth Doyle, Damien Fraysse

Biochem Soc Trans· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and optimization of selective protein kinase C θ (PKCθ) inhibitors for the treatment of autoimmune diseases.
Juan-Miguel Jimenez, Dean Boyall, Guy Brenchley, Philip N Collier, Christopher J Davis, Adam P Curnock

J Med Chem· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-based optimization of aminopyridines as PKCθ inhibitors.
Juan-Miguel Jimenez, Christopher Davis, Dean Boyall, Damien Fraysse, Ronald Knegtel, Adam Curnock

Bioorg Med Chem Lett· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and structure-activity relationship of 3-aminopyrid-2-ones as potent and selective interleukin-2 inducible T-cell kinase (Itk) inhibitors.
Jean-Damien Charrier, Andrew Miller, David P Kay, Guy Brenchley, Heather C Twin, Adam P Curnock

J Med Chem· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing the role of multiple phosphoinositide 3-kinases in chemokine signaling: use of dominant negative mutants controlled by a tetracycline-regulated gene expression system.
Adam P Curnock, Yannis Sotsios, Stephen G Ward

Methods Mol Biol· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimal chemotactic responses of leukemic T cells to stromal cell-derived factor-1 requires the activation of both class IA and IB phosphoinositide 3-kinases.
Adam P Curnock, Yannis Sotsios, Karen L Wright, Stephen G Ward

J Immunol· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and characterisation of tetracycline-regulated phosphoinositide 3-kinase mutants: assessing the role of multiple phosphoinositide 3-kinases in chemokine signaling.
Adam P Curnock, Stephen G Ward

J Immunol Methods· February 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemokine signalling: pivoting around multiple phosphoinositide 3-kinases.
Adam P Curnock, Marisa K Logan, Stephen G Ward

Immunology· February 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis